
Vaccination Reduces Long COVID Risk, Studies Confirm
A phase 3 clinical trial suggests that the BCG vaccine, when administered during active COVID-19 infection, may reduce the risk of developing long COVID symptoms. The study, conducted by researchers at the State University of Campinas in Brazil, found that BCG recipients experienced fewer issues with hearing, sleep, concentration, memory, and vision at 6 and 12 months post-injection compared to those who received a placebo. The study highlights the potential of BCG immunotherapy for treating existing ailments rather than as a preventive measure.




